Financial News Feed

Stronger Sell Today ADAP ranks #4762 as SELL CANDIDATE. Weaker Sell
Today ADAP ranks #4762 as SELL CANDIDATE.

ADAP stock Adaptimmune Therapeutics plc

ADAP stock
Adaptimmune Therapeutics plc

The EBITDA Yield for Adaptimmune Therapeutics plc (NasdaqGS:ADAP) is -0.182293. The EBITDA Yield is a great way to determine a company’s profitability. This number is calculated by dividing a compan... Read more
Checking in on some valuation rankings, Adaptimmune Therapeutics plc (NasdaqGS:ADAP) has a Value Composite score of 89. Developed by James O’Shaughnessy, the VC score uses five valuation ratios. The... Read more
Nexteer Automotive Group Limited (SEHK:1316) has a current MF Rank of 1763. Developed by hedge fund manager Joel Greenblatt, the intention of the formula is to spot high quality companies that are tra... Read more
Today we are spotlighting shares of Adaptimmune Therapeutics plc (NasdaqGS:ADAP) and looking at how the firm stacks up in terms of valuation by the numbers. One of the most important ratios to look at... Read more
Stock market investors may be taking some time to review portfolio allocation. Rebalancing the portfolio may be necessary for some but not for others. Rebalancing the portfolio may help provide a stra... Read more
Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Monday. The firm currently has a $6.50 target pr... Read more
Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Monday. The firm currently has a $6.50 pr... Read more
ADAPTIMMUNE THERAPEUTICS PLC (NASDAQ:ADAP) Files An 8-K Other EventsItem 8.01 Other Events. On January7, 2019, Adaptimmune Therapeutics plc (the “Company” or “Adaptimmune”) issued a press rele... Read more
Adaptimmune Ther Ads (ADAP)’s indicators and moving averages are pointing to a potential reversal at the Chikou line has ducked under the Tenkan, indicating that a reversal of price might be nearing... Read more
BidaskClub upgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a sell rating to a hold rating in a research note released on Tuesday. A number of other brokerages also recently weighed in o... Read more
Tracking the longer-term indicators on shares of Adaptimmune Ther Ads (ADAP), we have noted that the 100-day moving average verse price signal is currently Sell. This is the signal from the 100-day MA... Read more
Shares of Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) have been assigned an average recommendation of “Buy” from the nine research firms that are presently covering the firm, MarketBeat reports... Read more
Brokerages predict that Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) will post $14.50 million in sales for the current quarter, according to Zacks. Two analysts have provided estimates for Adaptimmu... Read more
Adaptimmune Ther Ads (ADAP) is on trader’s radar as the shares have moved above the MACD Histogram line, indicating a bullish trend. Shares recently touched 5.75 on a recent bid. The MACD is calcula... Read more
Watching the technicals on shares of Adaptimmune Ther Ads (ADAP), we have recently noted that the Chaikin Oscillator is above zero. Traders may be following the stock over the next few trading periods... Read more

News Feed powered by

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank